Biofrontera Inc. Form 8-K Summary
Business context and reporting period
Biofrontera Inc. filed this Form 8-K regarding a Nasdaq continued-listing deficiency. The triggering event occurred on February 24, 2023, and the report was signed on March 2, 2023. The filing does not report financial results for a quarterly or annual period.
Key financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-financial metrics.
Material change versus the prior comparable period
On February 24, 2023, Nasdaq notified the company that its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price had remained below $1.00 per share for 30 consecutive business days.
The notice did not immediately affect the listing or trading of the company’s securities on The Nasdaq Capital Market.
Outlook, risks, contingencies, and unusual items
- The company had until August 23, 2023, a 180-calendar-day compliance period, to regain compliance.
- Compliance required a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the compliance period.
- If the deficiency was not cured, the company could have been eligible for an additional compliance period, subject to meeting applicable market-value and other initial-listing requirements and notifying Nasdaq of its intention to cure the deficiency, potentially through a reverse stock split.
- Nasdaq could ultimately issue a delisting notice if the company could not cure the deficiency or failed to satisfy other listing standards. The company could appeal a delisting determination to a Hearings Panel.
- Management stated that it would monitor the closing bid price and consider available options. The filing cautions that there was no assurance the company would regain compliance or maintain compliance with other Nasdaq requirements.
Investor verification points
- Verify whether Biofrontera subsequently regained compliance with Nasdaq’s minimum bid-price requirement.
- Check for any reverse stock split, additional compliance period, delisting notice, or appeal.
- Review subsequent filings for the effect of the listing deficiency on financing activities, trading liquidity, and shareholder dilution.
- Obtain separate periodic filings for the company’s revenue, profitability, cash flow, debt, and liquidity information, which are not included in this 8-K.